Interactions between metabotropic glutamate 5 and adenosine A2A receptors in normal and parkinsonian mice

Journal of Neuroscience

Volumn 25, Issue 45, 2005, Pages 10414-10419

  Kachroo, Anil ^a   Orlando, Lianna R ^a   Grandy, David K ^b   Chen, Jiang Fan ^a   Young, Anne B ^a   Schwarzschild, Michael A ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Adenosine; G protein coupled receptor; Knock out; Locomotion; Metabotropic; Parkinson's disease

Indexed keywords

2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; ADENOSINE A2A RECEPTOR; ADENOSINE A2A RECEPTOR ANTAGONIST; DOPAMINE; ISTRADEFYLLINE; METABOTROPIC RECEPTOR 5; METABOTROPIC RECEPTOR ANTAGONIST; RESERPINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DRUG POTENTIATION; FEMALE; FOREBRAIN; KNOCKOUT MOUSE; LOCOMOTION; MALE; MOTOR ACTIVITY; MOTOR PERFORMANCE; MOUSE; NEUROPHARMACOLOGY; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RECEPTOR BINDING; RECEPTOR INTRINSIC ACTIVITY;

2,3,4,5-TETRAHYDRO-7,8-DIHYDROXY-1-PHENYL-1H-3-BENZAZEPINE; ANALYSIS OF VARIANCE; ANIMALS; ANIMALS, NEWBORN; BEHAVIOR, ANIMAL; BLOTTING, WESTERN; DISEASE MODELS, ANIMAL; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; EXCITATORY AMINO ACID ANTAGONISTS; LOCOMOTION; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MOTOR ACTIVITY; PARKINSON DISEASE; PURINES; PYRIDINES; RECEPTOR, ADENOSINE A2A; RECEPTORS, DOPAMINE D2; RECEPTORS, METABOTROPIC GLUTAMATE; TIME FACTORS;

EID: 27744450594     PISSN: 02706474     EISSN: 02706474     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.3660-05.2005     Document Type: Article

References (35)

1. Bara-Jimenez W, Sherzai A, Dimitrova T, Favit A, Bibbiani F, Gillespie M, Morris MJ, Mouradian MM, Chase TN (2003) Adenosine A(2A) receptor antagonist treatment of Parkinson's disease. Neurology 61:293-29 6.
2. Bastia E, Xu YH, Scibelli AC, Day YJ, Linden J, Chen JF, Schwarzschild MA (2005) A crucial role for forebrain adenosine A(2A) receptors in amphetamine sensitization. Neuropsychopharmacology 30:891-900.
3. Battaglia G, Busceti CL, Molinaro G, Biagioni F, Storto M, Fornai F, Nicoletti F, Bruno V (2004) Endogenous activation of mGlu5 metabotropic glutamate receptors contributes to the development of nigro-striatal damage induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. J Neurosci 24:828-835.
4. Breysse N, Baunez C, Spooren W, Gasparini F, Amalric M (2002) Chronic but not acute treatment with a metabotropic glutamate 5 receptor antagonist reverses the akinetic deficits in a rat model of parkinsonism. J Neurosci 22:5669-5678.
5. Breysse N, Amalric M, Salin P (2003) Metabotropic glutamate 5 receptor blockade alleviates akinesia by normalizing activity of selective basal-ganglia structures in parkinsonian rats. J Neurosci 23:8302-8309.
6. Chen J-F, Huang Z, Ma J, Zhu J, Moratalla R, Standaert D, Moskowitz MA, Fink JS, Schwarzschild MA (1999) A(2A) adenosine receptor deficiency attenuates brain injury induced by transient focal ischemia in mice. J Neurosci 19:9192-9200.
7. 2 receptor knockout mice. Proc Natl Acad Sci USA 98:1970-1975.
8. Chen J-F, Xu K, Petzer JP, Staal R, Xu YH, Beilstein M, Sonsalla PK, Castagnoli K, Castagnoli Jr N, Schwarzschild MA (2001b) Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease. J Neurosci 21:RC143(1-6).
9. Chen JF, Steyn S, Staal R, Petzer JP, Xu K, Van Der Schyf CJ, Castagnoli K, Sonsalla PK, Castagnoli Jr N, Schwarzschild MA (2002) 8-(3-Chlorostyryl) caffeine may attenuate MPTP neurotoxicity through dual actions of monoamine oxidase inhibition and A2A receptor antagonism. J Biol Chem 277:36040-36044.
10. Coccurello R, Breysse N, Amalric M (2004) Simultaneous blockade of adenosine A2A and metabotropic glutamate mGlu5 receptors increase their efficacy in reversing parkinsonian deficits in rats. Neuropsychopharmacology 8:1451-1461.
11. Danielson TJ, Coutts RT, Coutts KA, Keashly R, Tang A (1985) Reserpine-induced hypothermia and its reversal by dopamine agonists. Life Sci 37:31-38.
12. Diaz-Cabiale Z, Vivo M, Del Arco A, O'Connor WT, Harte MK, Muller CE, Martinez E, Popoli P, Fuxe K, Ferré S (2002) Metabotropic glutamate mGlu5 receptor-mediated modulation of the ventral striopallidal GABA pathway in rats. Interactions with adenosine A(2A) and dopamine D(2) receptors. Neurosci Lett 324:154-158.
13. Domenici MR, Pepponi R, Martire A, Tebano MT, Potenza RL, Popoli P (2004) Permissive role of adenosine A2A receptors on metabotropic glutamate receptor 5 (mGluR5)-mediated effects in the striatum. J Neurochem 90:1276-1279.
14. Ferré S, Karcz-Kubicha M, Hope BT, Popoli P, Burgueno J, Gutierrez MA, Casado V, Fuxe K, Goldberg SR, Lluis C, Franco R, Ciruela F (2002) Synergistic interaction between adenosine A2A and glutamate mGlu5 receptors: implications for striatal neuronal function. Proc Natl Acad Sci USA 99:11940-11945.
15. Fuxe K, Agnati LF, Jacobsen K, Hillion J, Canals M, Torvinen M, Tinner-Staines B, Staines W, Rosin D, Terasmaa A, Popoli P, Leo G, Vergoni V, Lluis C, Ciruela F, Franco R, Ferré S (2003) Receptor heteromerization in adenosine A2A receptor signaling: relevance for striatal function and Parkinson's disease. Neurology 61:S19-S23.
16. 2A receptor antagonist istradefylline in advanced PD. Neurology 61:297-303.
17. Herzig V, Schmidt WJ (2004) Effects of MPEP on locomotion, sensitization and conditioned reward induced by cocaine or morphine. Neuropharmacology 47:973-984.
18. Kearney JA, Albin RL (1995) Adenosine A2 receptor-mediated modulation of contralateral rotation induced by metabotropic glutamate receptor activation. Eur J Pharmacol 287:115-120.
19. 14C]-2-deoxyglucose autoradiographic study. J Neurosci 17:4415-4425.
20. 2 dopamine receptor-deficient mice is determined by gene dosage, genetic background, and developmental adaptations. J Neurosci 18:3470-3479.
21. Lea PM, Movsesyan VA, Faden AI (2005) Neuroprotective activity of the mGluR5 antagonists MPEP and MTEP against acute excitotoxicity differs and does not reflect actions at mGluR5 receptors. Br J Pharmacol 145:527-534.
22. Marino MJ, Valenti O, Conn PJ (2003) Glutamate receptors and Parkinson's disease: opportunities for intervention. Drugs Aging 20:377-397.
23. Mathiesen JM, Svendsen N, Brauner-Osborne H, Thomsen C, Ramirez MT (2003) Positive allosteric modulation of the human metabotropic glutamate receptor 4 (hmGluR4) by SIB-1893 and MPEP. Br J Pharmacol 138:1026-1030.
24. McGeehan AJ, Janak PH, Foster Olive M (2004) Effect of the mGluR5 antagonist 6-methyl-2-(phenylethynyl)pyridine (MPEP) on the acute locomotor stimulant properties of cocaine, D-amphetamine, and the dopamine reuptake inhibitor GBR12909 in mice. Psychopharmacology (Berl) 174:266-273.
25. 2A receptor signaling. Proc Natl Acad Sci USA 100:1322-1327.
26. Ossowska K, Konieczny J, Wolfarth S, Wieronska J, Pile A (2001) Blockade of the metabotropic glutamate receptor subtype 5 (mGluR5) produces antiparkinsonian-like effects in rats. Neuropharmacology 41:413-420.
27. Pintor A, Pezzola A, Reggio R, Quarta D, Popoli P (2000) The mGlu5 receptor agonist CHPG stimulates striatal glutamate release: possible involvement of A2A receptors. NeuroReport 11:3611-3614.
28. Popoli P, Pezzola A, Torvinen M, Reggio R, Pintor A, Scarchilli L, Fuxe K, Ferré S (2001) The selective mGlu(5) receptor agonist CHPG inhibits quinpirole-induced turning in 6-hydroxydopamine-lesioned rats and modulates the binding characteristics of dopamine D(2) receptors in the rat striatum: interactions with adenosine A(2a) receptors. Neuropsychopharmacology 25:505-513.
29. Rodrigues RJ, Alfaro TM, Rebola N, Oliveira CR, Cunha RA (2005) Colocalization and functional interaction between adenosine A2a and metabotropic group 5 receptors in glutamatergic nerve terminals of the rat striatum. J Neurochem 92:433-441.
30. Shiozaki S, Ichikawa S, Nakamura J, Kitamura S, Yamada K, Kuwana Y (1999) Actions of adenosine A2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP. Psychopharmacology 147:90-95.
31. B and group I metabotropic glutamate receptors in the striatopallidal complex in primates. J Anat 196:555-576.
32. Spooren WP, Gasparini F, Bergmann R, Kuhn R (2000) Effects of the protypical mGlu(5) receptor antagonist 2-methyl-6-(phenylethynyl)-pyridine on rotarod, locomotor activity and rotational responses in unilateral 6-OHDA-lesioned rats. Eur J Pharmacol 406:403-410.
33. 2 receptors. Neuropharmacology 25:455-463.
34. Tatarczynska E, Klodzinska A, Chojnacka-Wojcik E, Palucha A, Gasparini F, Kuhn R, Pilc A (2001) Potential anxiolytic-and antidepressant-like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist. Br J Pharmacol 132:1423-1430.
35. 2A receptor antagonists in Parkinson's disease. Pharmacol Ther 105:267-310.